Fibroblast Cell Therapy for Aneurysm Regression and Vascular Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic interventions for aneurysms and aortic dissection are primarily surgical, carrying significant risks, and there is a need for non-surgical methods to address vascular degeneration and its consequences.
Innovation Solution
Administration of a therapeutically effective amount of a composition comprising fibroblast cell populations, either alone or in combination with agents that stimulate stem cells, to inhibit and/or reverse blood vessel degeneration, promote regeneration, and treat aneurysms, using fibroblasts from various sources such as blood, placenta, bone marrow, or adipose tissue, along with mobilization of endothelial progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical intervention is used to treat aneurysms and aortic dissection, then the condition can be addressed directly, but significant surgical risks are incurred
Solution Approach 1:
The patent replaces mechanical surgical intervention with a biological therapy system. Fibroblast cells are administered to patients to promote natural healing and regeneration of blood vessel walls, substituting the mechanical cutting and stitching of surgery with a biological regeneration process that reduces surgical risks while maintaining treatment effectiveness
2Reliability
If fibroblast cell therapy is administered to promote blood vessel regeneration, then vascular degeneration is reversed, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent employs fibroblast cells that naturally migrate to damaged blood vessel sites and self-organize to promote regeneration. The administered cells perform the therapeutic function autonomously without requiring complex external control systems, reducing protocol complexity while achieving reliable vascular regeneration through the body's own healing mechanisms
Data Source
AI summary
Embodiments of the disclosure include methods of inhibiting and/or reversing blood vessel degeneration in an individual by administering to the individual a therapeutically effective amount of a fibroblast cell population. In specific embodiments, the individual has one or more aneurysms. Also disclosed are methods of inhibiting development of aortic dissection and/or reversing blood flow abnormalities associated with aortic dissection. In specific cases the cells are CD73 -positive and/or CD56-positive.